New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib

References

• CalabresiEPetrelliFBonifacioAFPuxedduIAlunnoAOne year in review 2018: pathogenesis of rheumatoid arthritisClin Exp Rheumatol2018362175184
   PubMed Web of Science ®Google Scholar
• MyasoedovaEDavisJMCrowsonCSGabrielSEEpidemiology of rheumatoid arthritis: rheumatoid arthritis and mortalityCurr Rheumatol Rep201012537938520645137
   PubMedGoogle Scholar
• Gaujoux-VialaCGossecLCantagrelARecommendations of the French Society for Rheumatology for managing rheumatoid arthritisJoint Bone Spine201481428729724986683
   PubMed Web of Science ®Google Scholar
• SinghJASaagKGBridgesSL2015 American College of rheumatology guideline for the treatment of rheumetoid arthritisArthritis Rheumatol2016681126
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBijlsmaJEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnn Rheum Dis201776696097728264816
   PubMed Web of Science ®Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism19953867277357779114
   PubMed Web of Science ®Google Scholar
• ShiJGChenXLeeFThe pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteersJ Clin Pharmacol201454121354136124965573
   PubMed Web of Science ®Google Scholar
• KeystoneECTaylorPCDrescherESafety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateAnn Rheum Dis201574233334025431052
   PubMed Web of Science ®Google Scholar
• TanakaYEmotoKCaiZEfficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled studyJ Rheumatol201643350451126834213
   PubMed Web of Science ®Google Scholar
• FridmanJSScherlePACollinsRSelective inhibition of JAK1 and Jak2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050J Immunol201018495298530720363976
   PubMed Web of Science ®Google Scholar
• KremerJMGenoveseMCKeystoneEEffects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritisArthritis & Rheumatology201769594395228029752
   PubMed Web of Science ®Google Scholar
• O’SheaJJKontziasAYamaokaKTanakaYLaurenceAJanus kinase inhibitors in autoimmune diseasesAnn Rheum Dis201372suppl 2ii111ii11523532440
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyOlumiant^® – Summary of Product CharacteristicsEMA2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdfAccessed September 30, 2018
   Google Scholar
• U.S. Food and Drug Administration Drug Approval Package: Olumiant® (baricitinib) Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000TOC.cfmAccessed September 30, 2018
   Google Scholar
• GenoveseMCKremerJZamaniOBaricitinib in patients with refractory rheumatoid arthritisN Engl J Med2016374131243125227028914
   PubMed Web of Science ®Google Scholar
• GenoveseMCKremerJMKartmanCEResponse to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritisRheumatology201857590090829415145
   PubMed Web of Science ®Google Scholar
• SmolenJSKremerJMGaichCLPatient-reported Outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)Ann Rheum Dis201776469470027799159
   PubMed Web of Science ®Google Scholar
• DougadosMvan der HeijdeDChenY-CBaricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studyAnn Rheum Dis2017761889527689735
   PubMed Web of Science ®Google Scholar
• EmeryPBlancoRMaldonado CoccoJPatient-reported Outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritisRMD Open201731e00041028405473
   PubMed Web of Science ®Google Scholar
• TaylorPCKeystoneECvan der HeijdeDBaricitinib versus placebo or adalimumab in rheumatoid arthritisN Engl J Med2017376765266228199814
   PubMed Web of Science ®Google Scholar
• KeystoneECTaylorPCTanakaYPatient-reported Outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyAnn Rheum Dis201776111853186128798049
   PubMed Web of Science ®Google Scholar
• FleischmannRSchiffMvan der HeijdeDBaricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentArthritis & Rheumatology201769350651727723271
   PubMed Web of Science ®Google Scholar
• SchiffMTakeuchiTFleischmannRPatient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentArthritis Res Ther201719120828923098
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCSchlichtingDESafety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritisJ Rheumatol2018451142128811354
   PubMed Web of Science ®Google Scholar
• TanakaYIshiiTCaiZSchlichtingDRooneyTMaciasWEfficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension studyModern Rheumatology2018281202928440680
   PubMed Web of Science ®Google Scholar
• GenoveseMCSmolenJSTakeuchiTSafety profile of baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysisArthritis Rheumatol201769suppl 10 Abstract 511
   Google Scholar
• SmolenJSGenoveseMCTakeuchiTSafety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatmentJ Rheumatol201946171830219772
   PubMed Web of Science ®Google Scholar
• FleischmannRAlamJAroraVSafety and efficacy of baricitinib in elderly patients with rheumatoid arthritisRMD Open201732e00054629071120
   PubMed Web of Science ®Google Scholar
• DougadosMComorbidities in rheumatoid arthritisCurr Opin Rheumatol201628328228827027814
   PubMed Web of Science ®Google Scholar
• DougadosMSoubrierMAntunezAPrevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)Ann Rheum Dis2014731626824095940
   PubMed Web of Science ®Google Scholar
• PappKAMenterMARamanMA randomized phase 2B trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisBr J Dermatol201617461266127626800231
   PubMed Web of Science ®Google Scholar
• WallaceDJFurieRATanakaYBaricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet201839210143222231
   PubMed Web of Science ®Google Scholar
• Guttman-YasskyESilverbergJINemotoOBaricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyJ Am Acad Dermatol Epub201821
   Web of Science ®Google Scholar